<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tuominen S</submitter><funding>Turku University Foundation</funding><funding>Svenska Kulturfonden</funding><funding>Finnish Governmental Research Funding for Turku University Hospital</funding><pagination>1312-1326</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8113193</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>48(5)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Many malignant tumours have increased TSPO expression, which has been related to a poor prognosis. TSPO-PET tracers have not comprehensively been evaluated in peripherally located tumours. This study aimed to evaluate whether N,N-diethyl-2-(2-(4-([&lt;sup>18&lt;/sup>F]fluoro)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide ([&lt;sup>18&lt;/sup>F]F-DPA) can reflect radiotherapy (RT)-induced changes in TSPO activity in head and neck squamous cell carcinoma (HNSCC).&lt;h4>Methods&lt;/h4>RT was used to induce inflammatory responses in HNSCC xenografts and cells. [&lt;sup>18&lt;/sup>F]F-DPA uptake was measured in vivo in non-irradiated and irradiated tumours, followed by ex vivo biodistribution, autoradiography, and radiometabolite analysis. In vitro studies were performed in parental and</pubmed_abstract><journal>European journal of nuclear medicine and molecular imaging</journal><pubmed_title>Evaluation of [&lt;sup>18&lt;/sup>F]F-DPA as a target for TSPO in head and neck cancer under normal conditions and after radiotherapy.</pubmed_title><pmcid>PMC8113193</pmcid><funding_grant_id>260982</funding_grant_id><funding_grant_id>13142</funding_grant_id><funding_grant_id>139742</funding_grant_id><pubmed_authors>Rajander J</pubmed_authors><pubmed_authors>Keller T</pubmed_authors><pubmed_authors>Loyttyniemi E</pubmed_authors><pubmed_authors>Sandholm J</pubmed_authors><pubmed_authors>Tuominen S</pubmed_authors><pubmed_authors>Petruk N</pubmed_authors><pubmed_authors>Tuomela J</pubmed_authors><pubmed_authors>Lopez-Picon F</pubmed_authors><pubmed_authors>Eichin D</pubmed_authors><pubmed_authors>Verhassel A</pubmed_authors><pubmed_authors>Gronroos TJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Evaluation of [&lt;sup>18&lt;/sup>F]F-DPA as a target for TSPO in head and neck cancer under normal conditions and after radiotherapy.</name><description>&lt;h4>Background&lt;/h4>Many malignant tumours have increased TSPO expression, which has been related to a poor prognosis. TSPO-PET tracers have not comprehensively been evaluated in peripherally located tumours. This study aimed to evaluate whether N,N-diethyl-2-(2-(4-([&lt;sup>18&lt;/sup>F]fluoro)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide ([&lt;sup>18&lt;/sup>F]F-DPA) can reflect radiotherapy (RT)-induced changes in TSPO activity in head and neck squamous cell carcinoma (HNSCC).&lt;h4>Methods&lt;/h4>RT was used to induce inflammatory responses in HNSCC xenografts and cells. [&lt;sup>18&lt;/sup>F]F-DPA uptake was measured in vivo in non-irradiated and irradiated tumours, followed by ex vivo biodistribution, autoradiography, and radiometabolite analysis. In vitro studies were performed in parental and</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 May</publication><modification>2026-04-18T01:36:16.209Z</modification><creation>2022-02-10T10:21:17.367Z</creation></dates><accession>S-EPMC8113193</accession><cross_references><pubmed>33340054</pubmed><doi>10.1007/s00259-020-05115-z</doi></cross_references></HashMap>